GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study
Active, not recruiting · Not applicable · NCT06578741
Conditions: Abdominal Aortic Aneurysm, Pararenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm
At a glance
- Research payments reported, 2025
- $18,720
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 310
About the trial
- Sponsor
- W.L.Gore & Associates
- Tested
- GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) (device)
- Dates
- Started 2024-11-25; completion 2036-06-01
- Results posted
- Not yet
This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.
From ClinicalTrials.gov, last updated 2026-07-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
W. L. Gore & Associates, Inc. reported $18,720 in research payments for this study in 2025 (1 payments).
Products named: Gore Excluder Thoracoabdominal Branch Endoprosthesis
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.